Hewlett Packard Enterprise Co vs 10X Genomics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.15 (market cap $94.25B), while 10X Genomics Inc trades at $81.59 (market cap $10.07B). The key difference: Hewlett Packard Enterprise Co is far larger — about 9.4× 10X Genomics Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and 10X Genomics Inc for 91 Days on average.
| HPE | TXG | |
|---|---|---|
Market Cap | $94.25B | $10.07B |
Volume | 16,060,854 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $72.12 | $97.74 |
52-Week Low | $20.01 | $11.48 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $108.28B | $9.59B |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
HPE trades at $71.75, near its all-time high, with strong momentum driven by AI infrastructure demand. The stock has gained over 160% year-over-year and recently received a bullish upgrade from Daiwa. Recent earnings beats and a $1.2 billion AI server order from Vultr highlight operational strength. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026.
Outlook remains positive with AI-driven growth catalysts, though valuation multiples appear elevated. Key risks include execution on Juniper integration and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting limited near-term upside from current levels despite strong business momentum.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →